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Abstract
Objective Cerebrospinal fluid (CSF) biomarkers are shown
to facilitate a risk identification of patients with mild
cognitive impairment (MCI) into different risk levels of
progression to Alzheimer’s disease (AD). Knowing a
patient’s risk level provides an opportunity for earlier
interventions, which could result in potential greater benefits. We assessed the cost effectiveness of the use of CSF
biomarkers in MCI patients where the treatment decision
was based on patients’ risk level.
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Methods We developed a state-transition model to project
lifetime quality-adjusted life-years (QALYs) and costs for
a cohort of 65-year-old MCI patients from a US societal
perspective. We compared four test-and-treat strategies
where the decision to treat was based on a patient’s risk
level (low, intermediate, high) of progressing to AD with
two strategies without testing, one where no patients were
treated during the MCI phase and in the other all patients
were treated. We performed deterministic and probabilistic
sensitivity analyses to evaluate parameter uncertainty.
Results Testing and treating low-risk MCI patients was the
most cost-effective strategy with an incremental cost-effectiveness ratio (ICER) of US$37,700 per QALY. Our
results were most sensitive to the level of treatment
effectiveness for patients with mild AD and for MCI
patients. Moreover, the ICERs for this strategy at the 2.5th
and 97.5th percentiles were US$18,900 and US$50,100 per
QALY, respectively.
Conclusion Based on the best available evidence regarding
the treatment effectiveness for MCI, this study suggests the
potential value of performing CSF biomarker testing for
early targeted treatments among MCI patients with a narrow range for the ICER.

Key Points for Decision Makers
Treating MCI patients at low risk generated greater
benefits, although it may be counterintuitive.
With a high degree of uncertainty, the decision of
whether to treatment MCI patients or not based on
their risk levels may benefit from gathering more
information on the treatment effectiveness for MCI.

T. L. Michaud et al.

1 Introduction
Alzheimer’s disease (AD) is a devastating neurodegenerative disease that impairs memory, thought, and behavior;
reduces quality of life; and decreases survival. As more
people live long enough to become at-risk [1, 2], identifying patients early in the disease continuum for greater
benefits from the potential interventions may alleviate
some of the burden on patients, caregivers, and society
[3, 4].
Prior to AD diagnosis, most patients progress through a
prodromal stage called mild cognitive impairment (MCI)
[5], which is a stage characterized by early memory loss
but with relatively well-preserved activities of daily living.
On average, MCI patients face a 10–15% risk of progression to AD each year [5–10]. Identifying patients at risk for
progression to AD at an earlier stage provides an opportunity to make decisions about disease management plans
and financial arrangements while cognitive function is still
capable [11, 12], and to access interventions with diseasemodifying effects if they were to become available
[13, 14].
Cerebrospinal fluid (CSF), consisting of a concentration
of Ab1–42 (a biomarker of amyloid b deposition in the
brain), total tau, and phosphorylated tau proteins [15, 16],
are shown to facilitate the identification of MCI patients
who are at different risk levels of progression to AD
[13, 17–19] and are included in the currently proposed
diagnostic criteria for AD [13] and MCI [20]. Moreover,
they are also considered the most preferred biomarkers for
studying disease progression due to their unique clinical
features and low incidences of complications [21, 22].
Accordingly, several multidisciplinary working groups
have either recommended using CSF biomarkers in the
diagnostic workup of MCI patients [23] or proposed the
utilization of CSF biomarkers in informing the likelihood
of the progression to AD among MCI patients [4, 24].
There is currently no cure for AD. With a hypothetical
disease-modifying therapy (DMT), however, data from
several simulation models supported the benefits of early
identification at the prodromal or predementia stage using
various diagnostic tools such as florbetaben positron emission tomography [25], brain magnetic resonance imaging
[26], apolipoprotein e4 genetic test [27], or CSF biomarkers
[28, 29]. In addition, some models compared the strategy of
a DMT versus the strategy of no DMT in patients with MCI
(the decision to treat or not was not based on the testing
results) [30, 31]; others compared different diagnostic
strategies with these novel testing techniques as an add-on
to standard diagnostic procedures [25, 26, 28].
The potential value of these tools to facilitate the
detection of AD at an early phase is only considered

speculative [14] due to the scant evidence pertaining to the
effectiveness of existing treatments for MCI patients. Yet,
results of a randomized clinical trial (RCT) [32] and metaanalysis studies [33–37] showed the potential benefits of
cholinesterase inhibitors (ChEIs; e.g., donepezil, galantamine, and rivastigmine) to delay the progression from
MCI to AD. Additionally, it is suggested by the recent
revision of cost-effectiveness analysis (CEA) recommendations [38] that if a decision must be made (in our case
whether or not to intervene for MCI patients based on their
CSF biomarker test results), it should be made based on the
data availability. Given the clinical utility of CSF
biomarkers and the best available data on treatment
effectiveness, therefore, the objective of our study was to
determine the potential value of the use of CSF biomarker
testing in MCI patients by comparing various test-and-treat
strategies with strategies without test information. Here,
CSF biomarkers were used as a risk-stratification tool to
categorize patients into different risk levels of progression
to AD (instead of a diagnostic tool to dichotomize patients
into positive or negative testing results), and the decision to
treat was based on a patient’s risk level.

2 Methods
We developed a state-transition model to estimate the
costs, quality-adjusted life-years (QALYs), and cost
effectiveness of performing one-time CSF biomarker testing for a cohort of 65-year-old MCI patients and then
treating some of these patients with ChEIs based on their
biomarker test results. We used evidence from a primary
data analysis [19] and the published literature to derive
relevant parameters. Costs and health outcomes were discounted 3% annually per the US recommendation [39], and
the model cycle length was 1 year. We adopted a US
societal perspective and a lifetime horizon.
2.1 Model Structure
Figure 1 illustrates the model structure. MCI patients who
undergo biomarker testing are assigned a high-, intermediate-, or low-risk score that determines their risk of progressing to AD [19]. On the basis of this score, a subset of
patients would be treated with ChEI therapy in the MCI
stage. Providing treatment in this phase introduces a cost
and imposes a risk of experiencing side effects but also
might reduce a patient’s risk of developing AD. If MCI
patients progress to AD, whether treated or not, they progress through a series of health states defined by AD
severity (mild, moderate, or severe) and residential settings
(community or nursing home). Each year, patients are
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Fig. 1 Schematic diagram of CSF biomarker testing and subsequent treatment for patients with MCI. AD Alzheimer’s disease, CSF
cerebrospinal fluid, MCI mild cognitive impairment, NH nursing home, Rx treatment

allowed to transition to another health state (progress in
severity or transition to nursing home), remain in the same
health state, or die. Once AD patients enter a nursing home
we assumed that they would remain in the institution until
death [40], given that most patients entering the nursing
home have severe AD.
2.2 Treatment Strategies
Because MCI patients could be categorized into one of
three risk levels of progression to AD based on their CSF
biomarker testing results (a positive and ordinal relationship), we evaluated six test-and-treat strategies as follows:
1.

2.

3.

4.

5.

No testing and no MCI treatment Treat only when MCI
patients convert to AD and stop treatment when they
progress to the severe stage.
Test and treat high risk Test MCI patients and only
treat those with a high-risk result until AD conversion;
no treatment for low- and intermediate-risk patients
until they convert to AD and stop treatment when they
progress to the severe stage.
Test and treat high or intermediate risk Test MCI
patients and treat those with a high- or intermediaterisk result until AD conversion; no treatment for lowrisk patients until they convert to AD and stop
treatment when they progress to the severe stage.
Test and treat low risk Test MCI patients and treat
those with a low-risk result until AD conversion; no
treatment for high- and intermediate-risk patients until
they convert to AD and stop treatment when they
progress to the severe stage.
Test and treat low or intermediate risk Test MCI
patients and treat those with a low- or intermediate-risk
result until AD conversion; no treatment for high-risk

6.

patients until they convert to AD and stop treatment
when they progress to the severe stage.
No testing and treat all MCI patients Treat all MCI
patients and stop treatment when patients convert to
AD.

Because evidence on the treatment effectiveness for
MCI patients is indefinite, we assumed that if MCI patients
received treatment, they would not be eligible for ChEI
treatment if they converted to AD based on clinical expert
opinion. We tested this assumption in the sensitivity
analysis.
2.3 Model Parameters
Table 1 summarizes the parameter estimates and their 95%
confidence intervals (CIs) if available. Otherwise, we used
50% higher or lower than the mean as the upper bound and
lower bound for the parameter estimate [41].
2.3.1 Disease Progression
In previous work [19], we estimated annual transition
probabilities from MCI to AD for each risk group (high,
intermediate, and low) defined by CSF biomarker levels
using 6-year follow-up data from the Alzheimer’s disease
Neuroimaging Initiative with 195 MCI patients. In brief,
time-dependent receiver operator characteristic analysis
was used to choose the best combination of CSF
biomarkers on the longitudinal predictive ability for the
progression of AD for MCI patients. Baseline CSF biomarker levels were summarized into a multi-biomarker
score by multiplying the biomarker level with each of their
own
coefficients
([-0.006] 9 Ab1–42 ? 0.012 9 Ptau181p) [19], derived from the fitted Cox proportional
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Table 1 Parameter inputs for the state-transition model
Parameter

Mean

95% CI

Distribution

Annual probability of progression from MCI to AD by CSF biomarker scorea

Source
[19]

Low-risk group

0.064

0.01–0.16

Beta (2.46, 35.93)

Intermediate-risk group

0.108

0.03–0.22

Beta (4.05, 33.48)

High-risk group

0.244

0.17–0.33

Beta (27.89, 86.40)

Prevalence of MCI patients by risk levels

[19]

Low-risk group

0.6

Intermediate-risk group

0.2

High-risk group

0.2

Annual transition probability

[40, 79]

Stage to stage (AD)
Mild to moderate
Mild to severe

0.167
0.014

0.156–0.178
0.010–0.018

Beta (690.43, 3443.86)
Beta (59.63, 4199.86)

Moderate to severe

0.299

0.286–0.312

Beta (1355.02, 3176.83)

Mild AD

0.012

0–0.028

Moderate AD

0.034

0–0.069

Severe AD

0.066

0.005–0.128

0.11

0.055–0.165

0.84

0.70–1.02

Lognormal (-0.17, 0.096)

[36]

Mild to moderate

0.58

0.35–0.76

Lognormal (-0.55, 0.198)

Estimated by authors

Moderate to severe

0.95

0.64–1.41

Lognormal (-0.05, 0.114)

[42]

0.23

0.2–0.26

Beta (173.78, 581.77)

[43]

Community to nursing home

Excess mortality due to AD (additive effect)b

Beta (2.27, 186.70)
Beta (3.57, 101.46)
Beta (3.74, 52.91)
[53, 54]

Treatment effectiveness (RR)
MCI patients
AD patients

Treatment harm
Annual prob. of AE (control)
AEs in MCI (RR)

1.09

1.02–1.16

Lognormal (0.086, 0.033)

[36]

AEs in AD (RR)
Withdrawal due to AEc

2.09
0.18

1.81–2.40
0.13–0.22

Lognormal (0.736, 0.073)
Beta (41.67, 181.76)

[44]
[44]

Withdrawal due to non-AE in MCI

0.046

0.035–0.058

Beta (52.94, 1201.7)

Assumed

Withdrawal due to non-AE in AD

0.11

0.10–0.12

Beta (190.03, 1543.9)

Assumed

0.73

0.58–0.88

Beta (23.86, 8.82)

[27, 80]

Health utility
MCI
AD

[49]

Mild
Community

0.68

0.54–0.82

Beta (28.34, 13.34)

Nursing home

0.71

0.57–0.85

Beta (27.97, 11.42)

Moderate
Community

0.54

0.43–0.65

Beta (42.08, 35.85)

Nursing home

0.48

0.37–0.59

Beta (37.59, 40.72)

Community

0.37

0.29–0.45

Beta (67.3, 114.6)

Nursing home
AEd

0.31

0.24–0.38

Beta (51.72, 115.11)

0.95

0.916–0.976

Beta (190, 10)

[29]

Lumbar punctured

0.01

0.009–0.012

Beta (9800, 99)

Assumed, [52]

7467

3733–11,200

Gamma (15.36, 0.0021)

[56]

Severe

Cost (US$, per person-year)
MCI
Formal
Mild AD

[55]
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Table 1 continued
Parameter

Mean

Community

9380

Nursing home

50,865

95% CI
4690–14,070
25,432–76,297

Distribution

Source

Gamma (15.37, 0.0017)
Gamma (15.37, 3.06)

Moderate AD
Community

13,859

6929–20,788

Nursing home

55,362

27,681–83,043

Gamma (15.37, 0.0011)
Gamma (15.37, 2.81)

Severe AD
Community

20,889

10,445–31,334

Gamma (15.37, 7.46)

Nursing home

59,327

29,664–88,991

Gamma (15.37, 2.63)

Informal

[55]

Mild AD
Community

11,876

Nursing home

1267

Moderate AD
Community
Nursing home

20,559

5938–17,815

Gamma (15.37, 0.0013)

633–1900

Gamma (15.33, 0.0127)

10,279–30,838

Gamma (15.37, 7.58)

486–1459

Gamma (15.35, 0.016)

973

Severe AD
Community

20,724

Nursing home

1028

10,362–31,086
514–1542

Gamma (15.33, 0.0151)

Gamma (15.37, 7.52)

Drug (donepezil)

2884

1442–4325

Gamma (15.35, 0.0054))

AWP, [57]

Office visit due to treatment (per time)

83

42–125

Gamma (14.88, 0.1837)

[49]

CSF biomarker testing (per person)

324

162–487

Gamma (15.50, 0.0492)

[25]

AD Alzheimer’s disease, AE adverse event, AWP average wholesale price, CI confidence interval, CSF cerebrospinal fluid, MCI mild cognitive
impairment, RR relative risk
a

CSF biomarker scores were calculated by the equation: (-0.006) 9 Ab1–42 ? 0.012 9 P-tau181p [19]. The three risk groups were defined by
the quintiles of the scores: high risk (the 3rd, 4th, and 5th quintiles), intermediate risk (the 2nd quintile), and low risk (the 1st quintile). Annual
transition probability of each risk group was converted from the 6-year cumulative probability estimated by the Kaplan–Meier survival functions

b
Applied only to patients with severe AD and half of this to patients with moderate AD. We assumed MCI patients and patients with mild AD
have the similar background all-cause mortality rate in terms of age
c

Annual probability derived from 6-month data by the exponential function (0.18 = 1 - exp[-0.0964 9 2])

d

Incorporated as disutility due to the treatment or lumbar puncture

hazard model for the best combination of CSF biomarker.
The three risk groups were defined by the quintiles of the
multi-biomarker score: high risk (the 3rd, 4th, and 5th
quintiles), intermediate risk (the 2nd quintile), and low risk
(the 1st quintile). We calculated the cumulative probability
of progression to AD for each risk group using the Kaplan–
Meier survival functions. For each risk group, we converted the 6-year cumulative probability into an annual
probability of progression to AD (conditional on still being
in the MCI state) and used this annual probability in our
decision model, assuming a constant probability over the
6 years.
For transitions among AD stages, we used probabilities
estimated by Spackman et al., who analyzed data from the
Uniform Data Set of the National Alzheimer Coordinating
Center [40]. They reported estimated probabilities of stageto-stage transitions and probabilities of community-tonursing-home transitions conditional on AD stage. Based
on the rule of conditional probability, we calculated the

combined stage and nursing home transition probabilities
(e.g., moving from mild AD community setting to mild AD
nursing home) by multiplying these two transition probabilities together. We assumed that the risk of transitioning
from community to nursing home conditional on AD stage
is as reported and does not change for those persons who
progress to different AD stages within the year.
2.3.2 Treatment Effectiveness
A recent Cochrane review [36] reported the relative risk
(RR) of progression to dementia as 0.84 (95% CI
0.70–1.02) over 3 years (although effects for year 1 and
year 3 were borderline significant) in MCI patients treated
with a ChEI. Namely, it represents a 16% reduction of the
annual progression risk from MCI to AD. In our base-case
analysis we assumed that the effect persisted for only the
first 3 years of treatment based on the synthesized results
of the review.
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The effectiveness parameter of ChEI treatment applied
to patients with moderate AD was derived directly from an
RCT [42], but we computed the RR for patients with mild
AD using the data provided in the same RCT due to lack of
directly applicable information. The RRs were 0.58 (95%
CI 0.35–0.76) and 0.95 (95% CI 0.64–1.41) for patients
with mild AD and moderate AD, respectively. In other
words, mild AD patients treated with ChEIs experience a
42% reduction in the annual risk of transitioning to either
moderate or severe AD, whereas the reduction was 5% for
moderate AD patients receiving treatment transitioning to
severe AD.
2.3.3 Adverse Events (AEs) Associated with Treatment
We used the result from a systematic review [43] for the
annual risk of AEs (0.23) in the placebo arm of donepezil
trials for MCI patients as the baseline risk for both MCI
and AD patients receiving no treatment in our model. The
reported RR of overall AEs between the treatment and the
control groups for MCI patients was 1.09 (95% CI
1.02–1.16) [36]. For AD patients, we converted the
reported odds ratio (OR) [44] to RR using methods from
the Cochrane Handbook [45]. The converted RR was 2.09
(95% CI 1.81–2.40).
Despite a low frequency of complications for lumbar
puncture [46], such as post-lumbar puncture headache,
especially in the elderly population [47, 48], we took into
account AEs due to CSF biomarker testing in the present
study.
2.3.4 Withdrawal of Cholinesterase Inhibitor (ChEI)
Treatment
We assumed that if patients discontinued treatment, they
would experience the same risks of transitioning to the next
health state as untreated patients. We did not assume any
residual effects of treatment. In addition, MCI patients who
discontinued the treatment would not be subsequently
treated, even though they converted to AD. A systematic
review [44] of 10 RCTs examining the efficacy of ChEIs
among AD patients showed that more patients discontinued
therapy due to AEs in the treatment group (18%) than in
the placebo group (8%) within a study period of 6 months
for all but two studies. We derived an annual withdrawal
probability of 18% (95% CI 13–22%) conditional on
experiencing an AE. Due to data availability, we applied
this annual probability derived from AD patients to MCI
patients as MCI is considered as the prodromal stage of AD
[5] and the medication considered in the present study is
one of the ChEIs. We also calculated the annual probability
of withdrawal from treatment due to other reasons (excluding AEs) as 4.6% (95% CI 3.5–5.8%) and 11% (95%

CI 10–12%) for MCI and AD patients receiving treatment,
respectively.
2.3.5 Health Utilities
We assigned health-related quality-of-life weights to disease severity and residential settings based on analyses by
Neumann et al. [49, 50], because it was one of the few
studies that estimated health utilities for joint states
defined by disease severity and residential settings. In the
study, they acquired quality-of-life weights, stratified by
disease stage and setting, using the Health Utilities Index
Mark II (HUI:2), which was administered in a companion,
cross-sectional study of 528 caregivers of AD patients in
the US [50]. Caregivers were asked to answer the questionnaire as the proxy respondents. Later, the responses to
the questionnaire were converted into preference weights
using the HUI:2 multi-attribute utility function [51]. Due
to the absence of a range of quality-of-life weights by
residential settings reported in their study, we applied the
estimates of the standard error for AD patients dwelling
in the community to AD patients in the nursing home. In
addition, we also accounted for the quality-of-life decrement resulting from AEs due to the treatment, which was
specified at 0.05 [29] as long as the treatment was provided. This disutility was accounted for by multiplying
the assigned utility for each relevant state (e.g., MCI,
mild AD, or moderate AD) by 0.95. The one-time disutility of 0.01 following the lumbar puncture (for CSF
biomarker testing) was derived from the literature where
the assumption was made [52].
2.3.6 Excess Mortality
The annual excess mortality rate among patients with
severe AD was estimated at 0.11 by the additive model
[53, 54]. We assumed that patients with moderate AD
would experience half of the excess rate (i.e., we added
0.055 to the background death rates for patients in the
moderate AD stage) and tested this assumption with a
multiplier (range 10–90%) of excess mortality in the sensitivity analysis. We assumed that this additive effect is the
same regardless of the patients’ age or gender [53]. We
assumed that the mortality rate for patients in the MCI and
mild AD stage is equal to the background all-cause mortality rate.
2.3.7 Costs
We took a modified US societal perspective to include
medical costs, and time costs of informal caregiving in the
CEAs. In addition, the healthcare sector perspective (informal costs excluded) was also considered.
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Formal and informal care We used the cost estimates reported
by Leon et al. [55] for patients with AD based on severity and
residential (community or nursing home) setting. These costs
include both formal (paid health services) and informal care
(defined as paid and unpaid services) for AD patients, where
informal costs were estimated by replacement wages. We
converted monthly costs to annual costs to assign to the relevant health states in our model. Because the variance (95%
CI) of costs was not reported in the study, we assumed that the
cost estimate for each health state in the model was 50% lower
or higher from the mean of point estimates for the lower bound
and the upper bound, respectively.
For the costs incurred in the MCI stage, we used data from
Leibson et al. [56] to inform formal healthcare costs, including
medical costs, pharmaceuticals, and informal healthcare costs
(home care, assisted living, and transport) for MCI patients.
We did not account for the non-healthcare direct costs
resulting from the loss of productivity of patients due to
disease progression because we targeted the 65-year-old
population. The CEA results presented included both formal and informal costs unless specified.
Medication We based the unit costs for AD medications on
the average wholesale price reported in the Red Book [57].
The daily costs for these drugs were calculated based on
their recommended dose and usage from the licensed
labels. Because the drug is currently off-patent, we derived
the medication cost at the available market price (US$7.79)
per day (the cost for donepezil 5 mg is the same as 10 mg)
and the largest pack size. We estimated the annual drug
costs as 365.25 9 US$7.79 = US$2845. For the follow-up
cost due to the treatment, we continued the assumption
made by a previous study [49] that donepezil would induce
two and one extra office visits every year along with the
treatment effect duration for MCI and AD patients,
respectively. One office visit was associated with US$82 as
estimated by the previous study [49].
CSF biomarker testing The cost of CSF biomarker analysis, a one-time cost per patient, was estimated using the
cost data from Centers for Medicare and Medicaid Services
hospital outpatient fee schedule [25].
Because the ChEI treatment-induced AEs are generally
mild or moderate [36, 58], we did not consider the costs of
treating AEs but the disutility associated with those AEs.
All cost estimates were inflated to 2016 US dollars using
the Consumer Price Index [59] if needed.
2.4 Analyses
2.4.1 Base-Case Analysis
We calculated expected discounted lifetime costs and discounted QALYs, generated from the probabilistic

sensitivity analysis (PSA) to account for the nonlinear
feature of Markov models [60, 61], for each of the six
strategies with the best estimates for all of the input
parameters and preferred set of assumptions. Results were
presented as incremental cost-effectiveness ratios (ICERs),
measured as the additional cost per additional QALY
gained. The most effective strategy with an ICER that is
below the designated willingness-to-pay (WTP) threshold
(i.e., the ratio of US$100,000 per QALY suggested by
Neumann et al. [62] in the US setting) would be declared as
a cost-effective strategy. After the cost-effective strategy
was decided, we further calculated its ICER in the 2.5th
and 97.5th percentiles using the same PSA results mentioned above.
2.4.2 Sensitivity Analysis
We conducted deterministic sensitivity analyses and PSA
to evaluate uncertainty with respect to all the parameters
included in the simulation models. Table 1 presents the
parameter values and their corresponding distributions.
To ensure only meaningful scenarios, we required that
the rank order of QALY weights in each PSA iteration
was aligned with disease severity and residential settings
[63], which implied that the health utility of
u(MCI) [ u(mild AD) [ u(moderate AD) [ u(severe
AD) and u(community) [ u(nursing home), applying the
preference-ordering algorithm developed by GoldhaberFiebert and Jalal [64]. We presented PSA results using
the cost-effectiveness acceptability curve (CEAC) [65],
and further plotted the cost-effectiveness acceptability
frontier (CEAF) [66, 67] on the top of CEAC to
simultaneously present the optimal strategy and the level
of uncertainty associated with that strategy at different
WTP thresholds.
2.4.3 Scenario Analysis
We conducted the scenario analysis, assuming patients are
allowed to receive treatment in the AD stage even if they
were treated in the MCI stage, because this is the standard
of care, even though the effectiveness of MCI treatment is
unclear. Because it is not known whether treatment effectiveness for AD is the same for treated and untreated MCI
patients, we further examined diminished treatment effectiveness in the AD stage for treated MCI patients. For
untreated MCI patients, the treatment effectiveness in the
AD stage was held constant at the base-case value (RR
0.58).
All analyses were performed in TreeAge Pro 2016
(TreeAge Software, INC, Williamstown, MA, USA), and
Microsoft Excel (Microsoft Corp., Redmond, WA, USA).
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3 Results

3.3 Probabilistic Sensitivity Analysis

3.1 Base-Case Analysis

Figure 2 shows the CEAC and the CEAF generated from our
PSA. With the maximized expected outcomes shown in the
base-case analysis, the strategy of testing and treating MCI
patients at low risk showed a 26% probability of being costeffective at a WTP of US$100,000 per QALY, whereas it was
30% for no testing and no MCI treatment. Testing and treating
MCI patients at low risk was the strategy with the highest
probability of being cost effective (29%) for a WTP of
US$150,000 per QALY. Strategies of testing and treating high
risk, and testing and treating high or intermediate risk showed
a lower likelihood of cost-effectiveness compared with other
test-and-treat strategies. They were less likely to be costeffective when WTP was higher than US$30,000 per QALY.

Table 2 shows discounted costs and discounted QALYs
for each strategy (the disaggregated total costs and
QALYs by health states for each strategy is presented in
Appendix A and B, respectively. In addition, we summarized the costs of medication, office visits, and CSF
biomarker testing separated from total costs by disease
stages and settings in Appendix C, see electronic supplementary material [ESM]). The most effective and most
costly strategy was to test and treat MCI patients at low
risk, which resulted in an ICER of US$37,700 per QALY
compared with not testing and not treating any MCI
patient. The ICERs for this strategy at the 2.5th and
97.5th percentiles were US$18,900 and US$50,100 per
QALY, respectively. In addition, results indicated that
testing and treating patients at low risk was still the most
cost-effective strategy with an ICER of US$59,800 per
QALY from a healthcare sector perspective (see Appendix D and E for disaggregated costs results in the ESM).
3.2 Deterministic Sensitivity Analysis
Table 3 summarizes the selected one-way sensitivity
analysis results with ICERs and corresponding comparators
for the key parameters (see Appendix F in the ESM for
results with the remaining parameters). Our base-case
results were most sensitive to variations in the effectiveness of treatment. For example, if the treatment effectiveness for mild AD patients was better than our base-case
estimate, or the treatment effectiveness for MCI patients
was worse than our base-case estimate, then no testing and
no MCI treatment would be cost-effective. Our results were
also sensitive to the health utility assigned to patients in the
MCI stage. The cost of medication (donepezil) had little
impact on our base-case results.

Table 2 Base-case results (per
patient) of performing CSF
biomarker testing and
subsequently treating MCI
patients based on their risk
levels of progression to AD

3.4 Scenario Analysis
As expected, QALYs increased with the increasing number of
treated MCI patients and the strategy of no testing and treating
all MCI patients was associated with the highest cost and
highest QALYs, with an ICER of US$27,600 per QALY,
given the relaxed assumption that patients are allowed to
receive treatment in the AD stage even if they were treated in
the MCI stage. All of the testing strategies were either strongly
or weakly dominated. In addition, results of examining the
diminished AD treatment effectiveness for treated MCI
patients and a constant AD effectiveness for untreated MCI
patients indicated that the strategy of no testing and treating all
MCI patients remained the best strategy when the RR of the
treatment effectiveness for AD was not worse than 0.65 at a
WTP threshold of US$100,000 per QALY (not shown).

4 Discussion
In this study, we sought to evaluate the potential value of
using CSF biomarkers to target treatments, based on the
best available data, for a subset of MCI patients according
ICER (US$/QALY)a

Strategy

Cost (US$)

QALYs

Test and treat high or intermediate risk

270,593

7.471

Test and treat high risk

270,735

7.475

No testing and treat all MCI patients

271,083

7.509

12,800

No testing and no MCI treatment

275,302

7.627

Weakly dominated

Weakly dominated

Test and treat low or intermediate risk

276,286

7.647

Weakly dominated

Test and treat low risk

276,428

7.651

37,700

If patients received treatment in the MCI stage, no treatment would be provided when they convert to AD
AD Alzheimer’s disease, CSF cerebrospinal fluid, ICER incremental cost-effectiveness ratio, MCI mild
cognitive impairment, QALYs quality-adjusted life-years
a

The value was rounded to the nearest $100. A weakly dominated strategy is a strategy with a higher
ICER than a more costly strategy
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Table 3 Incremental cost-effectiveness ratios of one-way sensitivity analysis results with key parameters
Analysisa

Base-case

Test-and-treat strategy
Test and
treat low
risk

Test and treat
low or
intermediate
risk

No test and
no MCI
treatment

No test
and treat
all MCI

Test and
reat high
risk

Test and treat
high or
intermediate
risk

37,700b

Weakly DOM

Weakly DOM

12,800c

Weakly DOM

–

Weakly DOM

Weakly DOM

19,000c

Weakly DOM

–

b

–

Weakly DOM

Weakly DOM

–

Weakly DOM

Annual probability of progression from MCI to AD
At low risk, 1%

38,500b

At low risk, 16%

Weakly DOM

Weakly DOM

35,600

At intermediate risk, 3%

Weakly DOM

40,700b

Weakly DOM

20,400c

At intermediate risk, 22%

38,100

b

c

Weakly DOM

Weakly DOM

9400

Weakly DOM

–

At high risk, 17%

64,400d

Weakly DOM

36,200b

9500c

Strongly DOM

–

At high risk, 33%

64,400d

Weakly DOM

38,000b

9500c

Strongly DOM

–

Mild AD, 0.35

Strongly DOM

Strongly DOM

16,400e

Strongly
DOM

7500c

–

Mild AD, 0.76

Strongly DOM

438,000b

Strongly
DOM

5800c

Strongly DOM

–

Moderate AD, 0.64

199,000d

Strongly DOM

27,800b

8800c

Weakly DOM

–

b

9500c

Strongly DOM

–

Treatment effectiveness (RR)

Moderate AD, 1.41

64,400

MCI patients, 0.70
MCI patients, 1.02

d

Weakly DOM

37,300

Strongly DOM

131,800b

Strongly
DOM

–

Strongly DOM

Strongly DOM

Strongly DOM

Strongly DOM

10,300e

Strongly
DOM

–

Strongly DOM

Annual prob. of AE (control), 20%

75,300d

Strongly DOM

34,400b

9300c

Strongly DOM

–

Annual prob. of AE (control), 26%

65,200

d

Weakly DOM

36,600

b

9600c

Strongly DOM

–

AEs in MCI (RR), 1.02

69,600d

Weakly DOM

37,500b

8600c

Strongly DOM

–

AEs in MCI (RR), 1.16

64,700d

Weakly DOM

33,300b

10,200c

Strongly DOM

–

AEs in AD (RR), 1.81

79,200d

Strongly DOM

33,400b

9400c

Strongly DOM

–

AEs in AD (RR), 2.40

Strongly DOM

Strongly DOM

10,200b

Strongly
DOM

–

Strongly DOM

Withdrawal due to AE, 13%

78,700d

Strongly DOM

44,500b

7500c

Strongly DOM

–

Withdrawal due to AE, 22%

d

10,700c

Weakly DOM

–

Weakly DOM

Treatment harm

64,800

b

Weakly DOM

35,600

Strongly DOM

26,500e

Health utility
MCI patients, 0.58
MCI patients, 0.88

995,200d

b

15,400c

–

Weakly DOM

c

6200

Strongly DOM

–

Strongly DOM

52,800

AE, 0.916

53,500f

53,000d

44,900b

8600c

Strongly DOM

–

AE, 0.976

84,900d

Strongly DOM

31,700b

10,300c

Strongly DOM

–

b

c

Health utility

d

Lumbar puncture, 0.009

78,600

Strongly DOM

35,500

9000

Strongly DOM

–

Lumbar puncture, 0.012

61,300d

Weakly DOM

37,300b

9700c

Strongly DOM

–

72,100d

Strongly DOM

35,500b

8600c

Strongly DOM

–

10,200c

Strongly DOM

–

Annual costs
MCI, US$3733

d

MCI, US$11,200
67,800
Weakly DOM
Formal costs for patients dwelling in the community
Mild AD, US$4690

96,600d
f

Mild AD, US$14,070

95,400

Moderate AD, US$6929

59,100d

Moderate AD, US$20,788

80,400

d

35,500

b

Strongly DOM

14,300e

Weakly DOM

–

Strongly DOM

b

Strongly
DOM

–

Strongly DOM

Strongly DOM

Weakly DOM

42,100b

4400c

Strongly DOM

–

Weakly DOM

b

14,500c

Weakly DOM

–

60,400

28,900
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Table 3 continued
Analysisa

Test-and-treat strategy
Test and
treat low
risk

Test and treat
low or
intermediate
risk

No test and
no MCI
treatment

No test
and treat
all MCI

Test and
reat high
risk

Severe AD, US$10,445

53,900f

47,000b

Weakly DOM

Severe AD, US$31,334

d

78,600

Test and treat
high or
intermediate
risk

1300c

Strongly DOM

–

Weakly DOM

36,100

b

21,500e

7400c

–

Formal costs for patients dwelling in a nursing home
Mild AD, US$25,432

75,900d

Weakly DOM

26,800b

17,600e

10,700c

–

Mild AD, US$76,297

57,000d

Weakly DOM

45,300b

3400c

Strongly DOM

–

Moderate AD, US$27,681

62,800

d

Weakly DOM

38,200

b

c

8700

Strongly DOM

–

Moderate AD, US$83,043

70,800d

Weakly DOM

35,200b

9900c

Strongly DOM

–

Severe AD, US$29,664

62,500f

49,700b

Weakly DOM

1600c

Strongly DOM

–

Severe AD, US$88,991

88,700d

Weakly DOM

22,700e

Weakly DOM

2400c

–

Multiplier, 10%

74,700d

Weakly DOM

26,200b

20,800e

6200c

–

Multiplier, 90%

d

Strongly DOM

–

Excess mortality in moderate AD
57,800

Strongly DOM

44,600

b

c

2200

The comparator strategy for the calculation of ICERs was varied by the value of parameters tested
AD Alzheimer’s disease, AE adverse event, DOM dominated, ICERs incremental cost-effectiveness ratios, MCI mild cognitive impairment, RR
relative risk
a
The value was rounded to the nearest $100. – indicated the reference strategy. A weakly dominated strategy is a strategy with a higher ICER
than a more costly strategy, and a strongly dominated strategy is a strategy that is more costly but less effective
b
Compared with no testing and treat all MCI patients
c

Compared with test and treat high or intermediate risk

d

Compared with no testing and no MCI treatment

e

Compared with test and treat high risk

f

Compared with test and treat low or intermediate risk

0.7

Probability that a strategy is cost-eﬀecve

Fig. 2 Cost-effectiveness
acceptability curve showing the
probability that a strategy is
cost-effective at various
willingness-to-pay thresholds.
Vertical lines represent the
incremental cost-effectiveness
ratio for strategies of ‘no testing
and treat all MCI patients’
(US$12,800/QALY), and ‘test
and treat low risk’ (US$37,700/
QALY). CEAF costeffectiveness acceptability
frontier, MCI mild cognitive
impairment, QALYs qualityadjusted life years

Test & treat low risk
Test & treat low or intermediate risk

0.6

No tesng & no MCI treatment
No tesng & treat all MCI paents
Test & treat high risk

0.5

Test & treat high or intermediate risk
CEAF

0.4
0.3
0.2
0.1
0
0

10k

20k

30k

40k

50k

60k

70k

80k

90k

100k

110k

120k

130k

140k

150k

Willingness to Pay (US$/QALY)

to their risk level of progression to AD. Our results indicated that testing and treating patients at low risk was costeffective with an ICER of US$37,700 per QALY, which
was more beneficial than treating patients at high risk,
although such a practice would be contradictory to the

widely held belief that interventions should usually be
aimed at high-risk patients. However, the low-risk patients
in our case were not comparable to the low-risk patients in
the general population. They were instead low-risk patients
among the MCI population—that is, referred to specialty
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clinics—and thus have a higher risk of progression to AD
than the general population. Thus, the conventional rationale (targeting high-risk patients) might not be applicable
in our case. Moreover, this finding may be associated with
our assumption that treated MCI patients were ineligible
for treatment if they converted to AD, and that MCI
patients at higher risk faced a relative short time until
clinical diagnosis of AD in our model [68, 69]. As a result,
the trade-off between treatment effectiveness for MCI
patients and for patients with mild AD was a key driver of
this finding. With the more conservative assumption of
treatment effectiveness for MCI patients utilized here when
compared with other published models using a hypothetical
DMT(RR 0.5) [29, 30, 70, 71], our finding may provide a
more realistic picture of potential treatment effectiveness
for MCI and AD patients.
Another possible explanation for the study finding is that
treatment duration for MCI patients at high risk may be
truncated (as we assumed the maximum treatment period
was 3 years based on the available evidence) due to the
conversion to AD. However, with results showing that time
in MCI stage (without intervention) was 3.16, 6.48, and
8.67 years for patients at high, intermediate, or low risk,
respectively, and a constant probability of transitioning
from MCI to AD for high-risk patients was 0.244 annually,
the treatment duration was less likely to be truncated at
Year 3 for this group. It is also possible that the treatment
response varied by MCI patients’ CSF biomarker profiles
(i.e., patients at high risk had a better response to the ChEI
therapy than patients at intermediate or low risk). By
assuming that MCI patients at high, intermediate, and low
risk had 100%, 80%, and 60% response to ChEI treatment,
respectively, results of additional analyses indicated that no
testing and no MCI treatment was cost-effective with an
ICER of US$30,000 per QALY, while it was US$106,300
per QALY for treating patients at low risk (results not
shown).
As indicated in the study by Sköldunger et al. [31],
patients will live longer as a consequence of the treatment,
and in turn accrue higher costs if providing treatment in the
AD stage but not in the MCI stage. In our case, the strategy
of ‘no testing and no MCI treatment’ reflected highest costs
in the mild AD stage (due to the treatment costs and longer
period in the mild AD stage, Appendix G, see ESM) but
lowest costs in the moderate and severe AD stage. This
may be explained by (1) a great difference between the
treatment effectiveness for mild AD (RR 0.58) and moderate AD (RR 0.95), which implies that there is almost no
treatment effect for moderate AD; (2) the time difference
in the states (Appendix G, see ESM); and (3) age- and
disease severity-related mortality rates. In this strategy,
simulated patients were older when they progressed to
moderate AD (6.285 QALYs in the MCI and mild AD

stage), and thus with higher mortality rates, compared with
the relatively younger population (6.023 QALYs in the
MCI and mild AD stage) in the strategy of ‘no testing and
treat all MCI patients’. Moreover, due to the modest
treatment effectiveness for moderate AD, simulated
patients with moderate AD either progressed to severe AD
or death quickly. In addition, our findings are in line with
the Sköldunger et al. study [31] oppositely with more time
in the MCI stage and less time in the AD stage as a whole
(the condensing effect) when treating MCI but not AD (no
testing and treat all MCI patients).
It is of value to investigate the feasibility of the treatment continuum from MCI to AD stages. Not surprisingly,
the scenario analysis where treatment was allowed in both
MCI and AD stages produced greater benefits than when
treatment was only allowed in one or the other. This
implied that alternative interventions that allowed for the
effectiveness to be carried over from MCI to AD stages
would be considered as an optimal strategy. Furthermore,
sensitivity analyses with a diminished AD treatment
effectiveness for treated MCI patients and a constant
effectiveness for untreated MCI patients indicated that no
testing and treating of all MCI patients was cost-effective if
the AD effectiveness for treated MCI patients was not
worse than RR 0.65.
Although previous studies concluded that CSF biomarker testing could allow one to identify MCI patients
who are best suited for potential pharmacological treatment
[19], this study suggests that treating low-risk MCI patients
might lead to a greater benefit by slowing the progression
to AD. That is to say, clinicians or policy makers might
consider the potential to intervene not only on higher-risk
patients but on low-risk MCI patients when they initiate the
disease management plan. Moreover, with the plausibility
that MCI patients at high risk may be close to the threshold
of AD diagnosis and that MCI patients in general are at a
higher risk for progression than the general population, the
findings again suggest that the MCI population might
benefit greatly from early intervention with the use of CSF
biomarker testing from a cost-effectiveness perspective.
Further studies are needed to re-evaluate the benefits of
early detection or diagnosis when the DMT is available.
It is possible that the most cost-effective (optimal)
strategy may not have the highest probability of being costeffective [67]. In our case, the strategy of testing and
treating patients at low risk was most cost-effective in the
base-case analysis; however, its probability of being costeffective in the PSA was only 26% at a WTP of
US$100,000 per QALY. The results showed that there is a
high degree of decision uncertainty surrounding the optimal strategy in the present study even with the best
available evidence. In this case, the decision of whether to
treat MCI patients or not may benefit from conducting
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value of information analysis to assess the potential gains
to further research [72] such as gathering more information
on the key parameters (i.e., the treatment effectiveness for
MCI), before making a decision. However, there is a tradeoff between the potential gain for more research and the
concurrent consequences (loss of potential benefits from
early interventions) of not taking any action.
Our study has several limitations. Our modeling results
were heavily subject to the inconclusive findings of treatment effectiveness. The treatment effectiveness of ChEIs
for MCI patients was derived from a recent Cochrane
review study [36] where authors reported evidence of
minor benefits (effects for year 1 and year 3 were borderline significant; effects for year 2 were significant) with
limitations and uncertainty, and further concluded that
ChEI treatment is not recommended for MCI patients due
to weak evidence. Compared with other similar studies
using a hypothetical treatment effectiveness (RR 0.5)
[29–31, 70, 71, 73], however, our assumption was relatively conservative (RR 0.84) and was based on point
estimates reported from the most recent review evidence.
Moreover, by applying the empirical data, our approach
should better reflect what the real potential treatment
benefits might be, acknowledge the debate of whether we
should treat MCI patients or not based on the current evidence, and reflect that if a decision must be made, it should
be made based on the available evidence [38].
No recent meta-analyses of treatment effectiveness for
AD patients were presented as the measure of the RR,
which was built-in in our model to reflect the treatmentassociated reduction on the risk of progression between the
AD stages. Most studies [44, 74, 75] reported the effect
size of this parameter as the point difference of cognitive
tests, such as Mini-Mental State Examination (MMSE) or
the AD and Associated Disorders Cognitive Scale between
treatment and control arms instead of the risk reduction of
transitions to more severe stages of AD (presented as the
RR). Hence, we applied the information from point differences of MMSE scores along with the proportion of
patients with mild AD and moderate AD in an RCT to
indirectly derive the RR of progression from the mild to
moderate AD stage for the treatment group versus the
control group.
The cost information [55] applied in this study is outdated due to the unavailability or inapplicability of recent
data. Changes in many social and cultural factors are very
likely to influence the cost estimates. However, we found
that our base-case findings were robust under wide ranges
of cost estimates examined in sensitivity analyses.
We were not able to account for the possible double
treatment effects, which may lead to a potential bias of
the study findings, resulting from the treatment effect
embedded in the estimated transition probabilities derived

from the scholarly literature where about 70% of their
analysis sample were reported using AD medication.
However, the cost-effectiveness metrics (ICERs) were the
relative difference between the different test-and-treat
strategies in terms of accrued costs and QALYs. In this
case, the treatment effects should be compensated or
minimal, which should not have major impact on our
findings.
We acknowledge several limitations, such as solely
using cognition as a driver of disease progression or a
limited number of health states to present the natural history of disease due to the use of Markov modeling techniques [76, 77] existing in the current simulation models in
AD. However, to build a model including indicators other
than cognitive function would increase the complexity of
the model structure, the trade-off between the complexity
and transparency of a simulation model should be well
balanced. The merit of using Markov models is that they
provide a relatively transparent analysis and accessibility
when compared with other models, such as discrete-event
simulation models, which may induce overspecification
where models may become more complex than necessary
(as a result of computational challenges) to elicit accurate
results [78].
We included a subset of all possible test-and-treat
strategies in the CEA. Our rationale is that we attempted to
find a threshold of CSF biomarker levels (a positive and
ordinal association with risk levels of AD) that would
decide which subset of MCI patients to treat from a costeffectiveness perspective. Therefore, it would not be logical to include strategies of ‘treat MCI patients at intermediate risk only’ or ‘treat MCI patients at low or high risk’ in
the CEA due to the ordinal nature of the risk levels.
Moreover, results of additional analyses including these
two strategies indicated that they were both weakly dominated strategies.
For the transitions in the residential settings, we
assumed once AD patients enter a nursing home they
would remain in the institution until death. This may not
reflect the current practice that patients transition among
hospitals, home, and long-term care facilities within a short
period of time. However, in our case, most of the patients
who entered the nursing facility had severe AD. Accordingly, given the similar disease severity, the accumulative
healthcare costs of staying in the nursing facility should be
similar to the transitions among hospitals, home or longterm care facilities within the same periods of time from a
social perspective.
We acknowledge that using CSF biomarkers only to
categorize MCI patients into different risk levels of progression to AD may omit the potential added values from
including other risk factors, such as patient demographics
and their clinical characteristics.
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5 Conclusion
Based on the best available evidence regarding treatment
effectiveness for MCI, this study suggests that performing
CSF biomarker testing for early targeted treatments among
MCI patients may be cost-effective. Interpretation of these
results should be made with caution. Further research is
needed to reduce the high degree of uncertainty regarding
testing and treating MCI patients.
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